Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EsoDuo for Reflux Symptom Control
NCT06430047Phase 4Recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esomeprazole + sodium bicarbonate in gastroesophageal reflux disease (GERD), sponsored by Chong Kun Dang Holdings. Primary endpoint: The time taken to control the symptoms of GERD at 2 weeks. Started Nov 2022; status: recruiting.
02
Drugs
esomeprazole + sodium bicarbonate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06430047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430047.